肿瘤坏死因子α拮抗剂与维得利珠单抗在老年炎症性肠病患者中的安全性和有效性比较:一项多中心研究
这项多中心回顾性研究纳入131例接受抗TNF治疗和103例接受维得利珠单抗治疗的60岁以上炎症性肠病患者,比较1年内感染或恶性肿瘤发生率及3、6、12个月临床缓解率。结果显示两组安全性无显著差异,感染率分别为20%和17%(P=0.54);抗TNF组克罗恩病患者3个月缓解率高于维得利珠单抗组(OR 2.82,95%CI 1.18-6.76),但6和12个月时差异未维持。结论认为两类药物在老年炎症性肠病患者中有效性和安全性相似。
要点
- 老年炎症性肠病患者中抗TNF与维得利珠单抗1年内感染或恶性肿瘤发生率无显著差异。
- 抗TNF组克罗恩病患者3个月临床缓解率高于维得利珠单抗组(OR 2.82,95%CI 1.18-6.76)。
- 6和12个月时两组临床缓解差异未维持,提示两类药物长期疗效相似。
核心结论
- 抗TNF和维得利珠单抗治疗在老年炎症性肠病患者中有效性和安全性相似。
研究设计与样本
- 多中心回顾性研究,纳入三个研究中心的60岁以上克罗恩病或溃疡性结肠炎患者,其中抗TNF组131例、维得利珠单抗组103例,年龄范围60-88岁。
主要发现
- 1年内抗TNF组感染发生率为20%,维得利珠单抗组为17%(P=0.54),两组安全性无显著差异。
- 肺炎是两组最常见的感染。
- 抗TNF组克罗恩病患者3个月临床缓解率高于维得利珠单抗组(OR 2.82,95%CI 1.18-6.76),但6和12个月时差异未维持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age. METHODS: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites. We examined occurrence of infection or malignancy within 1 year after therapy as our primary outcome. Our efficacy outcomes included clinical remission at 3, 6 and 12 months. Multivariable logistic regression models adjusting for relevant confounders estimated odds ratios (OR) and 95% confidence intervals. RESULTS: The study included 131 anti-TNF and 103 VDZ initiated patients (age range 60-88 years). Approximately half had CD. At 1 year, there were no significant differences in safety profile between the two therapeutic classes. Infections were observed in 20% of anti-TNF-treated and 17% of VDZ-treated patients (P = 0.54). Pneumonia was the most common infection in both groups. While more anti-TNF-treated CD patients were in remission at 3 months compared to VDZ (OR 2.82, 95% CI 1.18-6.76), this difference was not maintained at 6 and 12 months suggesting similar efficacy of both classes. CONCLUSIONS: Both anti-TNF and VDZ therapy were similarly effective and safe in elderly IBD patients.
引用
- Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019. PMID: 30773667. doi:10.1111/apt.15177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。